Biochemical Engineering Special Interest Group
biological engineering professionals
10 February 2017

Witty's bet on vaccines pays off in GSK CEO's final full year

After nearly 10 years at the CEO post for GlaxoSmithKline, Andrew Witty is handing over the reins to a company that has been reshaped with a vaccines focus. And during Witty’s final full year at the drugmaker, that business segment outgrew each of GSK’s other units. GSK’s vaccines grew (PDF) 14% to £4.6 billion, or $5.73 billion, in 2016 sales, besting pharma’s growth rate of 3% and consumer health’s increase of 9% on the year. Still, vaccines made up just 16% of the company’s overall sales, compared to 58% for pharmaceuticals and 26% for consumer healthcare. Source: FiercePharma 10/2/2017

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).